
Multidrug-Resistant MCF-7 Cells: An Identity Crisis?

Two recent correspondences published in the Journal (1,2) labeled the MCF-7/ADR cell line—a multidrug-resistant (MDR) human breast cancer MCF-7 subline—as having a non-MCF-7 origin, which led to a change in the nomenclature of this cell line to NCI/ADR. We believe the original nomenclature of MCF-7/ADR should be retained.

Although the two MDR MCF-7 sublines (MCF-7/ADR and MCF-7 TH) used by the investigators whose work prompted the nomenclature change were independently established, they showed several genotypic and phenotypic similarities. Both contained a full-length functional caspase-3 protein (2), despite complete loss of this protein in the parental MCF-7 cells because of a 47-base-pair deletion in exon 3 of the CASP-3 gene (3). Interestingly, several features of the MCF-7/DOX subline established in our laboratory several years ago (4) were identical to those of the MCF-7/ADR and MCF-7 TH cells but different from those of the parental MCF-7 cells (5). For example, similar to MCF-7/ADR and MCF-7 TH cells, the MCF-7/DOX cells showed high expression levels of P-glycoprotein (P-gp) and of a protein cross-linking enzyme, tissue transglutaminase; they also contained the full-length caspase-3 protein (6). We thus sought to determine whether the development of drug resistance in MCF-7 cells represents selective selection and expansion of an inherently resistant

clone in the parental MCF-7 cell population. We purchased MCF-7 cells from the American Type Culture Collection (lot 2015862; Manassas, VA) and treated them with doxorubicin at 1 $\mu\text{g}/\text{mL}$. More than 99% of the MCF-7 cells died within 1 week, but a few colonies (an average of two colonies per T-75 flask) were observed to grow in the presence of doxorubicin. Cells survived about 3 weeks of continuous culture in the presence of the drug. We expanded these colonies and, to our surprise, the newly established MCF-7 cell subline (MCF-7/WT/DOX) exhibited several biochemical features similar to those of the MCF-7/DOX and MCF-7/ADR cells but different from those of the parental MCF-7 cells. The MCF-7/WT/DOX cells showed high expression levels of both P-gp and tissue transglutaminase and contained full-length functional caspase-3 protein (Fig. 1, A). Karyotypic analysis of the MCF-7, MCF-7/DOX, and MCF-7/WT/DOX cell lines revealed unique features that were highly conserved in the drug-resistant sublines but were quite distinct in the parental MCF-7 cells (5).

MCF-7 cells express a truncated isoform of caspase-3 transcript, whereas drug-resistant sublines express full-length caspase-3 transcript. Thus, we amplified the complementary DNA (cDNA) from MCF-7 and MCF-7/WT/DOX cells by polymerase chain reaction (PCR) using primers specific for full-length caspase-3 cDNA to further vali-

date the presence of a drug-resistant clone in the parental MCF-7 cells. The resulting PCR products were analyzed for the presence of caspase-3 transcripts by agarose gel electrophoresis and ethidium bromide staining. The PCR products of the MCF-7 cells contained a predominant band corresponding to truncated caspase-3 transcript (Fig. 1, B); a minor band corresponding to full-length caspase-3 transcript became evident after many PCR cycles on the amplified cDNA (Fig. 1, B, arrow). The PCR-amplified products from the MCF-7/DOX cells showed only a single band, corresponding to the full-length caspase-3 transcript. These results confirmed the presence of one or more inherently resistant subclones in the parental MCF-7 cells that harbor the full-length CASP-3 gene and are likely to propagate into drug-resistant cell lines in the presence of MDR-related drugs. This possibility was further supported by our inability to establish any doxorubicin-resistant cell lines from two MCF-7 single-cell clones. These results appeared to be consistent with the findings that caspase-3-deficient MCF-7 cells, when reconstituted with caspase-3 cDNA, become more susceptible to chemotherapy-induced apoptosis (6). It is likely that caspase-3-adequate MCF-7 subclones that propagate into drug-resistant sublines have additional pathways that confer selective resistance of these cells to chemotherapeutic agents. Despite their high resistance to doxorubi-

cin, these cells are exquisitely sensitive to certain apoptosis-inducing agents. For example, Leoni et al. (7) observed that MCF-7/ADR cells were more sensitive to indanone-induced apoptosis than were the drug-sensitive MCF-7 cells. In our experience, the MCF-7/DOX cells were much more sensitive to a staurosporine-induced apoptosis than were the parental MCF-7 cells (5).

Our research has demonstrated that drug-resistant MCF-7 cell lines result from parental MCF-7 cells that harbor the full-length CASP-3 gene. In view of these results, we suggest that the original nomenclature of MCF-7/ADR for MCF-7-derived drug-resistant sublines be retained to reveal the fact that various clones in a given tumor population can be extremely diverse in terms of their genotype and phenotypic characteristics.

KAPIL MEHTA
ESWARAN DEVARAJAN
JACK CHEN
ASHA MULTANI
SEN PATHAK

REFERENCES

- (1) Scudiero DA, Monks A, Sausville EA. Cell line designation change: multidrug-resistant cell line in the NCI anticancer screen. *J Natl Cancer Inst* 1998;90:862.
- (2) Pirnia F, Breuleux M, Schneider E, Hochmeister M, Bates SE, Marti A, et al. Uncertain identity of doxorubicin-resistant MCF-7 cell lines expressing mutated p53. *J Natl Cancer Inst* 2000;92:1535-6.
- (3) Janike RU, Sprengart ML, Wati MR, Porter AG. Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis. *J Biol Chem* 1998;273:9357-60.
- (4) Mehta K. High levels of transglutaminase expression in doxorubicin-resistant human breast carcinoma cells. *Int J Cancer* 1994;58:400-6.
- (5) Devarajan E, Chen J, Multani AS, Pathak S, Sahin AA, Mehta K. Human breast cancer MCF-7 cell line contains inherently drug-resistant subclones with distinct genotypic and phenotypic features. *Int J Oncol* 2002;20:913-20.
- (6) Yang XH, Sladek TL, Liu X, Butler BR, Froelich CJ, Thor AD. Reconstitution of caspase-3 sensitizes MCF-7 breast cancer cells to doxorubicin- and etoposide-induced apoptosis. *Cancer Res* 2001;61:348-54.
- (7) Leoni LM, Hamel E, Genini D, Shih H, Carrera CJ, Cottam HB, et al. Indanone, a microtubule-binding indanone and a selective inducer of apoptosis in multidrug-resistant cancer cells. *J Natl Cancer Inst* 2000;92:217-24.

NOTES

Editor's note: Dr. Scudiero declined to comment.




Fig. 1. Tissue transglutaminase (tTGase) and caspase-3 expression in MCF-7, MCF-7/WT/DOX, and MCF-7/DOX cell lines. **A)** tTGase and caspase-3 protein expression levels were examined by western blot analysis in the parental MCF-7 cells (purchased from American Type Culture Collection; **lane 1**), in drug-resistant MCF-7/WT/DOX cells (obtained by continuous culture of the parental MCF-7 cells in doxorubicin at 1 $\mu\text{g}/\text{mL}$; **lane 2**), and in MCF-7/DOX cells (obtained from Dr. Ken Cowan, National Cancer Institute; **lane 3**). **B)** Caspase-3 transcripts in MCF-7 cells (**lane 1**) and MCF-7/WT/DOX cells (**lane 2**), as determined after many polymerase chain reaction cycles of the complementary DNA from the respective cell lines. **Arrow** indicates the presence of full-length caspase-3 transcript in MCF-7 cells.

Affiliation of authors: K. Mehta, E. Devarajan, J. Chen (Department of Bioimmunotherapy), A. Multani, S. Pathak (Department of Cancer Biology), The University of Texas M. D. Anderson Cancer Center, Houston.

Correspondence to: Kapil Mehta, Ph.D., Division of Cancer Medicine, Box 422, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030 (e-mail: kmehta@mdanderson.org).

RESPONSE

We read with great interest the correspondence by Mehta et al. These authors propose the hypothesis that the various doxorubicin (ADR)-selected MCF-7 sublines may result from the selective expansion of inherently resistant subclones that contaminate the parental MCF-7 cell line and that harbor the full-length CASP-3 gene. Although this theory is quite interesting, we have some caveats (1). Because the CASP-3 gene is deleted in parental MCF-7 (1), it is difficult to understand how this geno-

type could have been reverted in the hypothetically inherently resistant subclones (2). In our original description, we assessed the nonidentity of MCF-7 and MCF-7 TH by DNA fingerprinting (2). This method is more reliable than phenotypic karyotyping (3). When they claim that an inherently resistant subclone contains functional caspase-3, Mehta et al. somehow contradict the finding that caspase-3 restores chemotherapy sensitivity in MCF-7 cells (3).

Most importantly, Mehta et al. explain their hypothesis with a contamination of the parental MCF-7 cell line. Thus, we strongly caution against retaining the original nomenclature—MCF-7/ADR or MCF-7 TH—for these sublines of unknown origin. Good research cannot be performed with tools of uncertain identity.

FARZANEH PIRNIA
MARKUS M. BORNER

REFERENCES

- (1) Janicke RU, Sprengart ML, Wati MR, Porter AG. Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis. *J Biol Chem* 1998;273:9357–60.
- (2) Pirnia F, Breuleux M, Schneider E, Hochmeister M, Bates SE, Marti A, et al. Uncertain identity of doxorubicin-resistant MCF-7 cell lines expressing mutated p53. *J Natl Cancer Inst* 2000;92:1535–6.
- (3) Yang XH, Sladek TL, Liu X, Butler BR, Froelich CJ, Thor AD. Reconstitution of caspase-3 sensitizes MCF-7 breast cancer cells to doxorubicin- and etoposide-induced apoptosis. *Cancer Res* 2001;61:348–54.

NOTES

Affiliation of authors: F. Pirnia, M. M. Borner, Institute of Medical Oncology, Inselspital, Bern, Switzerland.

Correspondence to: Markus M. Borner, M.D., University of Bern, Institute of Medical Oncology, Inselspital, CH-3010 Bern, Switzerland (e-mail: markus.borner@insel.ch).